Sarepta Therapeutics (NASDAQ:SRPT) Given New $18.00 Price Target at Royal Bank Of Canada

Posted by Brenda Bartman on Nov 6th, 2026

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective upped by Royal Bank Of Canada from $17.00 to $18.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada‘s price target would suggest a potential upside of 1.52% from the company’s current price.

Several other brokerages have also recently weighed in on SRPT. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on Monday, September 28th. Benchmark reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, July 9th. Weiss Ratings cut shares of Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 28th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and seven have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $23.40.

Get Our Latest Analysis on SRPT

Sarepta Therapeutics Stock Up 0.9%

NASDAQ:SRPT traded up $0.16 during midday trading on Friday, reaching $17.73. The company had a trading volume of 1,492,540 shares, compared to its average volume of 3,001,938. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $24.68. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -6.17, a PEG ratio of 0.35 and a beta of 0.45. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. The stock’s fifty day simple moving average is $19.20 and its 200-day simple moving average is $18.66.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.06. The company had revenue of $381.35 million for the quarter, compared to analyst estimates of $352.20 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. Sarepta Therapeutics’s revenue for the quarter was down 4.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.13) EPS. On average, sell-side analysts anticipate that Sarepta Therapeutics will post 3.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pinnacle Wealth Planning Services Inc. increased its position in shares of Sarepta Therapeutics by 50.6% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,780 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 598 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Sarepta Therapeutics by 7.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock worth $190,000 after buying an additional 636 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in Sarepta Therapeutics by 3.1% in the first quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock valued at $626,000 after buying an additional 875 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 7.6% in the second quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 901 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 40.0% in the third quarter. Nisa Investment Advisors LLC now owns 4,555 shares of the biotechnology company’s stock valued at $83,000 after acquiring an additional 1,301 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics News Summary

Here are the key news stories impacting Sarepta Therapeutics this week:

Neutral Sentiment: Q3 revenue was $381.35 million, ahead of the cited $352.20 million estimate, but down 4.5% year over year. EPS improved from a loss a year earlier, though estimates differ on whether the quarter beat expectations. MarketBeat earnings report
Neutral Sentiment: A Sarepta–Hansa gene-therapy study update drew attention to the study’s end and raised questions for investors; the brief report does not provide enough detail to assess the clinical implications. Sarepta-Hansa study update
Negative Sentiment: Zacks characterized Q3 results as missing its earnings estimate and said weaker Elevidys sales weighed on sentiment, reinforcing concerns about the company’s near-term commercial performance. Zacks Q3 earnings and Elevidys sales report
Negative Sentiment: Baird lowered its price target to $18, a more cautious analyst outlook that may add pressure to the shares. Baird price-target update

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.